neuropeptide-y--leu(31)-pro(34)- and Stress-Disorders--Post-Traumatic

Topics: Amygdala; Animals; Arachidonic Acids; Arousal; Basolateral Nuclear Complex; Behavior, Animal; Benzamides; Carbamates; Depression; Disease Models, Animal; Endocannabinoids; Extinction, Psychological; Neuropeptide Y; Polyunsaturated Alkamides; Rats; Receptor, Cannabinoid, CB1; Receptors, Neuropeptide Y; Reflex, Startle; Social Behavior; Stress Disorders, Post-Traumatic

Exposure-based cognitive behavioral therapy in post-traumatic stress disorder (PTSD) patients relieves symptoms caused by fear association as well as symptoms that are not the result of associative learning. We used the inescapable foot shock model (IFS), an animal model for PTSD, to study the possible involvement of glutamate receptors, the corticotropin-releasing factor (CRF) system, and the neuropeptide Y (NPY) system in the reduction of stress sensitization following repeated re-exposure to the conditioning context. Starting one week after the IFS procedure, the rats were repeatedly re-exposed to the shock environment. Stress sensitivity was measured in a modified open field test (sudden silence was used as a stressor). Selected mRNAs (GluN1, -2A-C, GluA1-4, GluK1-5, CRF, CRF-R1, NPY, NPY-Y1) were quantified in the amygdala. Repeated re-exposure (RE) to the IFS context reduced both trauma-associated anxiety (to the IFS context) and the enhanced stress sensitivity (in the open field). Changes in glutamate receptor subunits (GluN1, GluN2A-B, GluA1, GluA4, GluK3, GluK4) were detected in the amygdala that were normalized by RE. However, infusion of the AMPA/kainate antagonist NBQX in the BLA (basolateral amygdala) did not improve the anxious behavior. RE normalized IFS-induced increases in CRF-R1 mRNA and increased NPY-Y1 mRNA expression in the amygdala. Previously, and repeated here, we showed that environmental enrichment (EE) enhances recovery from IFS. EE led to similar changes in CRF-R1 and NPY-Y1 expression as RE did. Importantly, administration of [Leu31, Pro34]-NPY (Y1 agonist) in the BLA normalized the enhanced sensitivity to stress after IFS. Our data suggest that the NPY-Y1 receptor in the amygdala may serve as a therapeutic target for the treatment of PTSD.

Topics: Amygdala; Animals; Behavior, Animal; Disease Models, Animal; Disease Susceptibility; Exploratory Behavior; Gene Expression Regulation; Male; Molecular Targeted Therapy; Nerve Tissue Proteins; Neurons; Neuropeptide Y; Neurotransmitter Agents; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Receptors, G-Protein-Coupled; Receptors, Kainic Acid; Receptors, Neuropeptide; RNA, Messenger; Socioenvironmental Therapy; Stress Disorders, Post-Traumatic